-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Arrowhead Pharma, Raises Price Target to $100

Benzinga·12/17/2025 12:20:24
Listen to the news
Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target from $70 to $100.